For decades, psychedelics sat firmly outside mainstream medicine. Magic mushrooms, LSD and other psychedelic compounds were largely associated with counterculture, underground therapists and small biotech companies trying to convince the world these substances deserved another look. But that story is changing rapidly.
Over the past few weeks, some of the world’s largest pharmaceutical companies have committed billions of dollars to psychedelic medicines, signalling what may be the industry’s biggest turning point yet.
Billions Are Flowing In
The clearest example came when pharmaceutical giant Eli Lilly agreed to acquire psychedelic drug developer Atai Beckley in a deal worth up to $3.8 billion.
It isn’t an isolated move. Japanese pharmaceutical company Otsuka recently acquired Transcend Therapeutics, while AbbVie purchased rights to Gilgamesh Pharmaceuticals’ lead psychedelic programme in a deal worth up to $1.2 billion. Just two years ago, this would have seemed unlikely.
In 2024, the FDA rejected Lykos Therapeutics’ MDMA-assisted therapy for PTSD, leading many commentators to question whether the psychedelic industry had peaked before it had truly begun. Instead, the opposite appears to be happening.
Why Now?
Several factors have converged. The biggest is data.
Recent late-stage clinical trials have produced encouraging results for psychedelic treatments targeting depression. Definium Therapeutics recently reported positive Phase 3 results for an LSD-based treatment for major depressive disorder. Compass Pathways also announced positive late-stage data for COMP360, its synthetic psilocybin therapy, showing sustained improvements in people with treatment-resistant depression. The company has since received accelerated regulatory review, bringing it one step closer to potential approval.
Investors are beginning to see psychedelics as something more than an interesting scientific experiment. They’re starting to look like a commercial opportunity.
The regulatory landscape is changing too. Earlier this year, the Trump administration signed an executive order aimed at accelerating research and approval pathways for psychedelic therapies.
While this doesn’t guarantee approvals, it signals growing political support for developing new treatments for conditions such as depression and PTSD, areas where many patients still fail to respond to existing medications.
The Possibilities
Big Pharma doesn’t have to imagine whether psychedelic-inspired medicines can become successful products. Johnson & Johnson’s ketamine-derived nasal spray, Spravato, generated $1.7 billion in sales last year, with revenue continuing to climb.
Although ketamine differs pharmacologically from classic psychedelics like psilocybin and LSD, it has demonstrated that entirely new approaches to treating mental health disorders can achieve widespread medical adoption. That success has likely increased confidence that other psychedelic therapies could eventually follow.
Despite the excitement, psychedelic medicines face obstacles that conventional pills do not.
While the compounds themselves are relatively inexpensive to manufacture, the real bottleneck is treatment delivery. Most psychedelic therapies require extensive preparation, trained therapists, dedicated treatment rooms and hours of supervision during and after dosing. Scaling that model across healthcare systems will be difficult and expensive. Companies are now exploring shorter-acting compounds, simplified treatment protocols and new formulations that could reduce the amount of clinical support required.
Whether those approaches retain the same therapeutic benefits remains one of the biggest unanswered questions in the field.
A Turning Point
Perhaps the biggest shift is cultural. For years, psychedelics were viewed as too controversial for mainstream pharmaceutical companies. Today, many of those same companies are actively acquiring psychedelic drug developers and investing billions into the space.
That doesn’t mean success is guaranteed. Clinical trials can still fail, regulators can still reject therapies, and commercial adoption remains uncertain.
But one thing now seems increasingly clear. Psychedelics are no longer a niche corner of medicine. They’ve become a serious area of investment, research and pharmaceutical development.
Whether that ultimately benefits patients will depend not only on the drugs themselves, but on whether the industry can preserve what has made psychedelic therapy unique while bringing it into mainstream healthcare.
The next chapter of psychedelic medicine may no longer be written by startups alone. It may be written by some of the largest pharmaceutical companies in the world.
Keep up with developments here.
